ArticleHeliyon2024
Nanoquantification of RUNX2 by a 1,1'-carbonyldiimidazole-diamond mediated sandwich assay for osteogenic differentiation.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adipose tissue-derived stem cells (ADSCs) possess the capability to modulate the immune response and alleviate inflammation, rendering them a promising therapeutic option for various conditions, including autoimmune diseases, cardiovascular diseases, and tissue injuries. The osteogenic differentiation in ADSCs plays a pivotal role in fracture healing, bone growth, and the overall bone turnover process, governed by intricate interactions. Runt-related Transcription Factor 2 (RUNX2) is a key player in mineralized tissue generation and is typically found in the early stages of osteogenic differentiation. The objective of this study was to develop a high-affinity sandwich biosensor for the quantification of RUNX2. 1,1'-Carbonyldiimidazole-modified nanodiamond was immobilized on an amine-modified interdigitated electrode surface, followed by the use of a capture antibody to facilitate antigen interaction. A sandwich assay was conducted with the antibody, and the limit of detection for RUNX2 was calculated as 0.1 ng/mL, with a regression value (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.